|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2021-06-04 |
/ Not yet recruiting临床1/2期 A Phase 1/2A Prospective, Dose-Escalation, Open-Label Study of the Safety, Feasibility, and Initial Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Diabetic Foot Ulcer
/ Not yet recruiting临床1/2期 A Phase 1/2A, Dose Escalation, Randomized, Placebo Controlled Study of the Safety, Feasibility, and Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Chronic Tympanic Membrane Perforation
/ Not yet recruiting临床2/3期 A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of ProMetic Plasminogen Intravenous Infusion in Subjects with Hypoplasminogenemia
100 项与 ProMetic Biotherapeutics Ltd. 相关的临床结果
0 项与 ProMetic Biotherapeutics Ltd. 相关的专利(医药)
100 项与 ProMetic Biotherapeutics Ltd. 相关的药物交易
100 项与 ProMetic Biotherapeutics Ltd. 相关的转化医学